Background: geno2pheno [coreceptor] is a bioinformatic method for genotypic tropism determination (GTD) which has been extensively validated. Objectives: GTD can be affected by sequencing/base-calling variability and unreliable representation of minority populations in Sanger bulk sequencing. This study aims at quantifying the robustness of geno2pheno [coreceptor] with respect to these issues. GTD with a single amplification or in triplicate (henceforth singleton/triplicate) is considered. Study Design: From a dataset containing 67,997HIV-1 V3 nucleotide sequences, two datasets simulating sequencing variability were created. Further two datasets were created to simulate unreliable representation of minority variants. After interpretation of all sequences with geno2pheno [coreceptor] , probabilities of change of predicted tropism were calculated. Results: geno2pheno [coreceptor] tends to report reduced false-positive rates (FPRs) when sequence alterations are present. Triplicate FPRs tend to be lower than singleton FPRs, resulting in a bias towards classifying viruses as X4-capable. Alterations introduced into nucleotide sequences by simulation change singleton predicted tropism with a probability ≤ 2%. Triplicate prediction lowers this probability for predicted X4 tropism, but raises it for predicted R5 tropism ≤ 6%. Simulated limited detection of minority variants in X4 sequences resulted in unchanged predicted tropism with probability above 90% as compared to probability above 98% with triplicate FPRs. Conclusions: geno2pheno [coreceptor] proved to be robust when sequence alterations are present and when detectable minorities are missed by bulk sequencing. Changes in tropism prediction due to sequence alterations as well as triplicate prediction are much more likely to result in false X4-capable predictions than in false R5 predictions.
Background
The Human Immunodeficiency Virus type 1 (HIV-1) employs two host molecules in order to enter the host cell: the CD4 receptor and a coreceptor. In vivo, either of two coreceptors can be: CCR5 and CXCR4. The capability to use a certain coreceptor is called Abbreviations: HIV-1, human immunodeficiency virus type 1; MVC, maraviroc; GTD, genotypic tropism determination; FPR, false-positive rate; V3, third hypervariable loop; EP, electropherogram dataset; ME, manually-edited sequence; AS, automatic sequence; SEP, single-electropherogram sequence; indel, insertion or deletion; LA, Los-Alamos dataset; SA, Sanger-alteration dataset; SE, single-error dataset; M, mixture dataset; MS, mixture-sampling dataset; CPT, change in predicted tropism; S, singleton; T, triplicate; SD, standard deviation.
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viral tropism. HIV-1 so-called R5 strains can only use CCR5. CXCR4-capable strains can use either CXCR4, exclusively (X4 strains), or both coreceptors (dual/mixed tropic viruses) [1] . Maraviroc (MVC) is an antiretroviral that inhibits HIV-1 entry into the cell by binding to CCR5, and is thus ineffective against X4-capable strains. Therefore, viral tropism determination must precede MVC prescription [2] . Tropism can be determined phenotypically or genotypically [3] [4] [5] [6] . Phenotypic determination in cell cultures is expensive, time-consuming, and requires specialized labs. Furthermore, samples with viral loads up to 1000 cp/ml often yield indefinite results, although proviral DNA testing is performed also [7] . Genotypic tropism determination (GTD) requires genotyping the third hypervariable loop of the HIV-1 env gene (V3) with subsequent computer-based interpretation. Several methods for interpreting sequences in order to determine HIV-1 tropism have been developed [6] . geno2pheno [coreceptor] [8] is an extensively validated bioinformatic method for GTD [3] [4] [5] [6] 9] ; its use as an alternative to phenotypic determination is recommended by the European and the Austrian-German HIV-treatment guidelines [12] [13] [14] .
geno2pheno [coreceptor] interprets V3 with a Support Vector Machine (SVM) trained on genotype-phenotype pairs. Geno2pheno [coreceptor] outputs the false-positive rate (FPR) 1 with X4-capable being defined as positive [8] . FPR dichotomization yields a (predicted) viral classification into X4-capable or R5. When the FPR is in a range where MVC antiviral action is considered possible, yet uncertain, the virus is classified as X4-capable. Alternatively, this intermediate FPR range can be explicitly labeled, as is customary for interpretation of drug resistance to other antiretroviral drugs. Thus, MVC administration with an FPR in the intermediate range could be made dependent on whether other therapy options co-exist, rather than excluding it altogether. Furthermore, the use of an intermediate category when determining tropism can also be appropriate for predictions with FPR-decreasing sequence alterations, especially when determining tropism in triplicate.
Establishment of the most suitable cutoff for FPR dichotomization has been a matter of substantial debate. Currently, there is no universally accepted cutoff.
Objectives
The input to geno2pheno [coreceptor] is aV3 sequence. Therefore, the quality of the predictions depends on the quality of these sequences. With Sanger bulk sequencing, the measured sequence is a consensus of the dominating strains in the viral population. Here, minorities comprising less than 10%-20% of the viral population are unreliably represented, due to the limits of the experimental technology. X4-capable minorities may render MVC ineffective. Therefore, some labs perform the amplification step of the sequencing procedure in triplicate [15] to increase the chances of detecting minorities. This analysis addresses two related, unresolved questions: (1) How robust is geno2pheno [coreceptor] with respect to sequencing/base-calling variability in terms of change of predicted tropism (CPT)? (2) What is the influence of undetected minority populations on the predictions of geno2pheno [coreceptor] ? Both issues are of critical importance for assessing the reliability of geno2pheno [coreceptor] for clinical purposes. This article aims at providing answers to both questions.
Study design
A dataset of 163,958HIV-1 V3 nucleotide sequences was downloaded from the Los Alamos National Laboratory (http://www.hiv.lanl.gov/) on September, 19th 2013. Nucleotide sequences with duplicate V3 regions were discarded, resulting in the Los-Alamos dataset (LA) comprising 67,997 nucleotide sequences. Subtypes in LA were determined with Comet [16] . LA was used to create further datasets by altering its sequences in silico.
The probability of each type of sequence variation (base exchanges, ambiguities, insertions/deletions [indels]) at each sequence position resulting from differential primer specificity, and misincorporation/indel events during the RT-PCR amplification and sequencing reactions was determined using 164 clinical blood samples obtained from the Department of Clinical Virology of the University of Cologne, as described in Section Supplementary methods. This knowledge was used to generate the Sangeralteration dataset (SA). The dataset contains 10 in-silico generated variants of each LA sequence. Alterations in these in-silico variants may be present at any of the 105 nucleotide positions.
The single-error dataset (SE) was created by generating sequences from each LA sequence by systematically exchanging every nucleotide in V3 by each of the 15 possible definite and ambiguous bases, independently of their probability of occurrence. Thus, from each sequence in LA, all possible sequences diverging by one definite or ambiguous base were generated.
The mixture dataset (M) was created from sequences in LA containing ambiguities (excluding N). Ambiguities in each of these sequences were combinatorially resolved into all possible sequence alternatives without ambiguities. To avoid combinatorial explosion, sequences that would result in more than 20,000 derived sequences were excluded from this procedure.
The mixture-sampling dataset (MS) was created to simulate a scenario in which sequencing depth is insufficient to resolve all sequence variants in the sample. From each sequence group in M derived from the same LA sequence, a certain proportion of sequences was extracted at random by uniform sampling without replacement, and a new sequence was created by retaining positions that are identical among the sequences in the subset and representing differential positions with the corresponding ambiguities. Proportions represent sequencing depth and ranged from 1% to 100% in steps of 2%; each sequence group was sampled 3 × 100 times (100 repetitions that allow for triplicate FPRs).
Sequences in LA, SA, SE, M, and MS were interpreted with geno2pheno [coreceptor] . For each sequence, the FPR shift was calculated as the difference between the FPR of the altered sequence and that of its unaltered counterpart in LA. When we consider n FPRs from variability-simulation replicates on the same sequence, we call singleton FPR the FPR obtained with the first sequence. For all further sequences, we take the minimum FPR among the first n and call it nth replicate FPR. The 3rd replicate FPR is also called triplicate FPR. geno2pheno [coreceptor] 's FPR was used to determine coreceptor tropism as X4-capbable or R5. Four different FPR cutoff sets were used for tropism determination:
• {20}: FPR < 20 ⇒ X4-capable, FPR ≥ 20 ⇒ R5 [13] According to Austrian-German treatment guidelines, MVC can be effective when a tropism prediction is labeled intermediate albeit with much less certainty than for R5 variants [14] .
The probability the tropism predicted by geno2pheno [coreceptor] changed due to the introduced sequence alterations was calculated by sample counting as P(T A,C | T U,C ), with T A,C denoting the tropism of the altered sequences as determined with cutoff set C, and T U,C denoting the tropism of the unaltered sequences as determined with cutoff set C. The reference sequence used to number V3 nucleotide positions is consensus B (105 nucleotides), which is the reference used by geno2pheno [coreceptor] .
Results
Alteration rates estimated for generation of SA (Section Supplementary methods) are shown in Supplementary Tables 1 and  2 .
The FPR distribution in LA is illustrated in Supplementary Fig.  1 . The numbers of strains by subtype are tabulated in Table 1 . In LA, 0.24% of the bases are ambiguous, while 99.76% of the bases are definite. Among the FPR shifts between the altered SA sequence and that of its unaltered counterpart in LA, 79% are equal to zero, 11% are below zero and 10% are above zero (see also Supplementary  Fig. 2 ). Fig. 1 shows how the probability of obtaining FPRs lower than the singleton FPR increases with the number of amplifications. Finally, Figs. 2 and 3 depict the change of predicted tropism (CPT) probabilities for different cutoff sets (probabilities labeled S for singleton FPRs and T for triplicate FPRs). Figs. 2 and 3 show that geno2pheno [coreceptor] is more likely to reduce than to raise FPR when sequence alterations are present, slightly favoring a false prediction of R5 viruses as X4-capable over the reverse misprediction (see also Supplementary Fig. 2 ). Since the FPR shifts are both negative and positive, FPR determination in triplicate will always reduce FPRs, as the minimum FPR is selected. When determining FPR in triplicate, there is a 27% chance that the triplicate FPR will be lower than the singleton FPR (Fig. 1 ). The overall average shift in SE is −2.22 (SD = 13.87); 23% of these shifts are zero, 36% are above zero and 40% are below zero ( Supplementary Fig. 3 ). Here again we see the tendency of geno2pheno [coreceptor] to reduce FPR when sequence alterations are present. Fig. 4 shows a plot of FPR shifts averaged by nucleotide position. Alterations in some parts of the V3 loop have a higher propensity for changing coreceptor tropism than others, as expected. The magnitude and sign of the average shifts vary greatly with the nucleotide position. Shifts averaged by nucleotide or ambiguity code can be seen in Table 2 .
In LA, 6133 sequences contained ambiguous bases. The sequences in the M dataset were derived from 6118 of these sequences by resolving their ambiguities. Fifteen sequences were excluded to avoid combinatorial explosion. Among the 6133 original sequences, 41% resulted in two derived sequences while 59% resulted in more than two sequences ( Supplementary Fig. 4 ). Supplementary Fig. 5 shows a plot of the average shift in MS against the sampling proportion, for triplicate and for singleton FPRs. The magnitude of the shift decreases as the proportion increases, and was zero for proportions of 85% of the sequences or more. The lowest proportion tested, 1%, yielded a mean singleton FPR shift of 0.61 (SD = 10.91), and a mean triplicate FPR shift of 
Discussion
This analysis addresses two related questions: the robustness of geno2pheno [coreceptor] with respect to sequence alterations in terms of change of predicted tropism, and the influence of minority populations on the predictions of geno2pheno [coreceptor] . Therefore, we have subjected geno2pheno [coreceptor] to a challenge involving the systematic introduction of simulated sequencing variability into a large set of V3 nucleotide sequences in order to generate four datasets: SA simulates alterations due to the Sanger Table 2 Mean FPR shift averaged by nucleotide base, SE dataset.The table shows the mean FPR shift and standard deviation (SD), averaged by substituting nucleotide base after alignment. Shifts were calculated by comparing FPRs in the SE dataset with their unaltered counterparts in the LA dataset. Although gaps were not considered when generating the SE dataset, some nucleotide alterations were transformed to gaps by the alignment program of geno2pheno [ An accurate study of the effect of sequencing X4-associated codons at amino-acid positions 11, 13, 24, 25, and 32 (nucleotide positions 30-33, 37-39, 69-72, 73-75, 94-96) more accurately by using specific primers has been studied [17] . The primer sets were specifically designed for subtype B. Our study has extended to other subtypes, as about half of the 67,997 sequences were non-Bs (Table 1) .
The FPR shifts between the original and the in-silico mutated sequences in SE have been analyzed (Fig. 4 and Table 2 ). 9.1% are less than −20 and 11% are greater than 10. These two shift values were chosen to be multiples of 10, close to the 10th and 90th percentile of the shift distribution. The shift cutoff −20 identifies amino-acid positions 7, 8, 11 (nucleotide positions 19-21, 22-24, 31-33) , and insertions after amino-acid positions 21, 22 and 23 (nucleotide positions 61-63, 64-66 and 67-69) as highly relevant for detection of CXCR4-capable viruses with geno2pheno [coreceptor] . Using a shift cutoff of 10, positions 9, 10, 17, 28 and 31 (nucleotide positions 25-27, 28-30, 48-51, 82-84, 91-93) are highly relevant for the detection of R5 viruses with geno2pheno [coreceptor] . Mean shifts averaged by nucleotide base are negative, unless the sequence alteration is replaced with a gap by the alignment program. The smallest mean shift is −4.85. These results indicate that the position at which the alteration occurs is far more important than the nucleotide base the alteration consists of, as might have been expected.
Triplicate sequencing is performed with the intention of improving the detection of X4-capable minority variants. In triplicate testing, the lowest FPR is considered the correct one, without comparing the obtained nucleotide sequences. Thus, if the lowest FPR is caused by a nucleotide sequencing error, triplicate testing will bias the prediction towards favoring X4-capable. If the obtained sequences are not manually inspected, errors in the individual sequences remain undetected. Thus, the more replications are sequenced, the higher the chance you get an FPR lower than the first one, even if X4-capable minority variants are absent. In this case, triplicate testing can result in an exclusion of MVC-eligible patients, without increasing the safety of the prediction.
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The lowest value obtained for the probability that there is no CPT is 90% with geno2pheno [coreceptor] . In order to put this number into context, we mention Trofile's reported sensitivity to detect MVC responders, 92% [11] .
geno2pheno [coreceptor] proved to be robust in the presence of sequence alterations and when detectable minorities are missed by bulk sequencing. False R5 predictions were either rare or absent in our analysis, depending on the selected cutoffs. If a CPT occurs, it is much more likely that sequence alterations result in false X4-capable predictions than false R5 predictions. This speaks for the safety of MVC prescription to patients with predicted R5 viruses.
